KAI-11101
KAI-11101 is the inhibitor for dual leucine zipper kinase (DLK, MAP3K12) with a Ki of 0.7 nM. KAI-11101 inhibits Paclitaxel -induced cJun phosphorylation (IC50=95 nM) and thus inhibits the activation of MAPK pathway. KAI-11101 is blood brain barrier penetrable and can be further investigated for its neuroprotective property[1].
Product Specifications
UNSPSC
12352005
Target
MAP3K; p38 MAPK
Related Pathways
MAPK/ERK Pathway
Field of Research
Neurological Disease
Smiles
O=C1C(N(CC)N=C2C3=CC(OC(F)F)=C(N)N=C3)=C2C=CN1[C@H]4[C@@H](OC)CC(F)(F)CC4
Molecular Formula
C21H23F4N5O3
Molecular Weight
469.43
References & Citations
[1]Lagiakos HR, et al., In Silico Enabled Discovery of KAI-11101, a Preclinical DLK Inhibitor for the Treatment of Neurodegenerative Disease and Neuronal Injury. J Med Chem. 2024 Dec 13.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC941796-100 1x 100 µL
CD22 / BL-CAM (B-Cell Marker) (BLCAM/1796), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC041627-100 1x 100 µL
CD79a (B-Cell Marker) (ZL7-4), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC882205-500 1x 500 µL
PGP9.5 / UchL1 (pan-Neuronal Marker) (rUCHL1/775), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details